The HFEA has approved applications by scientists from Kings College London and Newcastle University to carry out research using human-animal cytoplasmic hybrid embryos. The two applicants have been granted one-year research licences allowing the creation and use of human-animal cytoplasmic embryos from which embryonic stem cells may be removed.

The research aims to increase understanding of embryonic development and the genetic causes of neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.

Commenting on the HFEA decision, Dr Sophie Petit-Zeman, Head of External Relations at the AMRC said:

"This is good news for research, but most importantly it is good news for patients.

"The AMRC co-ordinated an appeal to Tony Blair last year, co-signed by 223 charities and patient groups, when there was a very real risk that the government would outlaw hybrid embryo research. We have worked hard with member charities, with policymakers, and with the media to help ensure an understanding of the potential patient benefit that would be lost if this work were not allowed to proceed, but we have never ignored the complex ethical and scientific debate that surrounds it.

"Hype must not now overtake reality, and a long process of rigorous research within a strict regulatory framework is needed to see whether the promise of this new technique can be realised. But today's decision is certainly a step in the right direction towards understanding and treating conditions like Alzheimer's, Parkinson's and other devastating ills."

17 January 2008

Dr Sophie Petit-Zeman can be reached for comment on 07799 764475